BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37598924)

  • 21. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway.
    Huang YF; Zhu DJ; Chen XW; Chen QK; Luo ZT; Liu CC; Wang GX; Zhang WJ; Liao NZ
    Oncotarget; 2017 Jun; 8(25):40264-40275. PubMed ID: 28402965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
    Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
    Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selenoprotein S silencing triggers mouse hepatoma cells apoptosis and necrosis involving in intracellular calcium imbalance and ROS-mPTP-ATP.
    Li X; Chen M; Yang Z; Wang W; Lin H; Xu S
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2113-2123. PubMed ID: 30017912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib and Ruthenium Complex Combination Inhibit Cancer Cell Growth by Targeting PI3K/AKT/ERK Signalling in Colorectal Cancer Cells.
    Sharma D; Rasool F; Bharti M; Vyas KM; Magani SKJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.
    Belli V; Sforza V; Cardone C; Martinelli E; Barra G; Matrone N; Napolitano S; Morgillo F; Tuccillo C; Federico A; Dallio M; Loguercio C; Gravina AG; De Palma R; Ciardiello F; Troiani T
    Oncotarget; 2017 Sep; 8(40):68305-68316. PubMed ID: 28978118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
    Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
    Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
    Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
    J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
    Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
    Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer.
    Torrens-Mas M; Hernández-López R; Oliver J; Roca P; Sastre-Serra J
    J Cell Physiol; 2018 Aug; 233(8):6067-6076. PubMed ID: 29323702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis-in vitro and in vivo.
    Yang YS; Wen D; Zhao XF
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jun; 394(6):1263-1274. PubMed ID: 33409556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    Al-Khayal K; Vaali-Mohammed MA; Elwatidy M; Bin Traiki T; Al-Obeed O; Azam M; Khan Z; Abdulla M; Ahmad R
    BMC Cancer; 2020 Jul; 20(1):685. PubMed ID: 32703189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.